Pediatric Infectious Disease

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  6 (2024)
Volume  5 (2023)
Volume  4 (2022)
Volume  3 (2021)
Volume  2 (2020)
Volume  1 (2019)
Related articles

VOLUME 4 , ISSUE 3 ( July-September, 2022 ) > List of Articles

REVIEW ARTICLE

Role of Infectious Agents in the Etiology of Kawasaki Disease

Aaqib Banday, Pandiarajan Vignesh, Surjit Singh

Keywords : Infections, Kawasaki disease, RNA virus, Superantigen, Wind hypothesis

Citation Information : Banday A, Vignesh P, Singh S. Role of Infectious Agents in the Etiology of Kawasaki Disease. Pediatr Inf Dis 2022; 4 (3):104-108.

DOI: 10.5005/jp-journals-10081-1233

License: CC BY-NC 4.0

Published Online: 31-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Abstract

Kawasaki disease (KD) is a multisystemic childhood vasculitis that predominantly affects the coronary arteries. The constellation of clinical features in KD, such as, acute onset of fever, redness of lips and oral mucosa, rash, swelling over palms and feet, cervical adenopathy, and perineal peeling followed by periungual peeling suggests an infection or toxin-mediated etiology. Occurrence of cases in clusters and epidemics also support an infectious etiology for KD. Many infectious agents—bacteria, fungi, and viruses—are reported to be associated with KD. This review article gives a comprehensive overview of available literature that supports an infective etiology for KD.

PDF Share
  1. Rowley AH, Eckerley CA, Jack HM, et al. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immunol 1997;159(12):5946–5955.
  2. Rowley AH, Shulman ST, Mask CA, et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis 2000;182(4):1183–1191. DOI: 10.1086/315832
  3. Rowley AH, Shulman ST, Spike BT, et al. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J Immunol 2001;166(2): 1334–1343. DOI: 10.4049/jimmunol.166.2.1334
  4. Rowley AH, Shulman ST, Garcia FL, et al. Cloning the arterial IgA antibody response during acute Kawasaki disease. J Immunol 2005;175(12):8386–8391. DOI: 10.4049/jimmunol.175.12.8386.
  5. Rowley AH, Baker SC, Shulman ST, et al. Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J Infect Dis 2005;192(10):1757–1766. DOI: 10.1086/497171
  6. Rowley AH, Baker SC, Shulman ST, et al. Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody. J Infect Dis 2004;190(4):856–865. DOI: 10.1086/422648
  7. Rowley AH, Baker SC, Shulman ST, et al. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS One 2008;3(2):e1582. DOI: 10.1371/journal.pone.0001582
  8. Rowley AH, Baker SC, Shulman ST, et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a “new” virus associated with Kawasaki disease. J Infect Dis 2011;203(7):1021–1030. DOI: 10.1093/infdis/jiq136
  9. Rowley AH, Wylie KM, Kim KY, et al. The transcriptional profile of coronary arteritis in Kawasaki disease. BMC Genomics 2015;16:1076. DOI: 10.1186/s12864-015-2323-5.
  10. Rowley AH, Shulman ST. The epidemiology and pathogenesis of Kawasaki disease. Front Pediatr 2018;6:374. DOI: 10.3389/fped.2018.00374
  11. Kontopoulou T, Kontopoulos DG, Vaidakis E, et al. Adult Kawasaki disease in a European patient: a case report and review of the literature. J Med Case Rep 2015;9:75. DOI: 10.1186/s13256-015-0516-9
  12. Johnson RM, Bergmann KR, Manaloor JJ, et al. Pediatric Kawasaki disease and adult human immunodeficiency virus Kawasaki-like syndrome are likely the same malady. Open Forum Infect Dis 2016;3(3):ofw160. DOI: 10.1093/ofid/ofw160
  13. Stankovic K, Miailhes P, Bessis D, et al. Kawasaki-like syndromes in HIV-infected adults. J Infect 2007;55(6):488–494. DOI: 10.1016/j.jinf.2007.09.005
  14. Thissen JB, Isshiki M, Jaing C, et al. A novel variant of torque teno virus 7 identified in patients with Kawasaki disease. PLoS One 2018;13(12):e0209683. DOI: 10.1371/journal.pone.0209683
  15. Bajolle F, Meritet JF, Rozenberg F, et al. Markers of a recent bocavirus infection in children with Kawasaki disease: “a year prospective study”. Pathol Biol (Paris) 2014;62(6):365–368. DOI: 10.1016/j.patbio.2014.06.002
  16. Maggio MC, Cimaz R, Alaimo A, et al. Kawasaki disease triggered by parvovirus infection: an atypical case repJ Med Case Report of two siblings. 2019;13(1):104. DOI: 10.1186/s13256-019-2028-5
  17. Guleria S, Jindal AK, Pandiarajan V, et al. Dengue-triggered Kawasaki disease: a report of 2 cases. J Clin Rheumatol 2018;24(7):401–404. DOI: 10.1097/RHU.0000000000000704
  18. Kuijpers TW, Tjia KL, de Jager F, et al. A boy with chickenpox whose fingers peeled. Lancet 1998;351(9118):1782. DOI: 10.1016/S0140-6736(98)04021-5
  19. Ogboli MI, Parslew R, Verbov J, et al. Kawasaki disease associated with varicella: a rare association. Br J Dermatol 1999;141(6):1145–1146. DOI: 10.1046/j.1365-2133.1999.03231.x
  20. Ueda Y, Kenzaka T, Noda A, et al. Adult-onset Kawasaki disease (mucocutaneous lymph node syndrome) and concurrent Coxsackievirus A4 infection: a case report. Int Med Case Rep J 2015;8:225–230. DOI: 10.2147/IMCRJ.S90685
  21. Kikuta H, Matsumoto S, Yanase Y, et al. Recurrence of Kawasaki disease and Epstein-Barr virus infection. J Infect Dis 1990;162(5):1215. DOI: 10.1093/infdis/162.5.1215
  22. Kanegane H, Tsuji T, Seki H, et al. Kawasaki disease with a concomitant primary Epstein-Barr virus infection. Acta Paediatr Jpn 1994;36(6):713–716. DOI: 10.1111/j.1442-200X.1994.tb03277.x
  23. Kikuta H, Taguchi Y, Tomizawa K, et al. Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature 1988;333(6172): 455–457. DOI: 10.1038/333455a0
  24. Marchette NJ, Melish ME, Hicks R, et al. Epstein-Barr virus and other herpesvirus infections in Kawasaki syndrome. J Infect Dis 1990;161(4):680–684. DOI: 10.1093/infdis/161.4.680
  25. Wang J, Sun F, Deng HL, et al. Influenza A (H1N1) pdm09 virus infection in a patient with incomplete Kawasaki disease: a case report. Medicine (Baltimore) 2019;98(15):e15009. DOI: 10.1097/MD.0000000000015009
  26. Hu P, Guan Y, Fan XC, et al. Incomplete Kawasaki disease induced by measles in a 6-month-old male infant. Int J Dermatol 2016;55(1):e34–e36. DOI: 10.1111/ijd.13122
  27. Turnier JL, Anderson MS, Heizer HR, et al. Concurrent respiratory viruses and Kawasaki disease. Pediatrics 2015;136(3):e609–e614. DOI: 10.1542/peds.2015-0950
  28. Suenaga T, Suzuki H, Shibuta S, et al. Detection of multiple superantigen genes in stools of patients with Kawasaki disease. J Pediatr 2009;155(2):266–270. DOI: 10.1016/j.jpeds.2009.03.013
  29. Matsubara K, Fukaya T, Miwa K, et al. Development of serum igm antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease. Clin Exp Immunol 2006;143(3):427–434. DOI: 10.1111/j.1365-2249.2006.03015.x
  30. Yoshioka T, Matsutani T, Iwagami S, et al. Polyclonal expansion of TCRBV2- and TCRBV6-bearing T cells in patients with Kawasaki disease. Immunology 1999;96(3):465–472. DOI: 10.1046/j.1365-2567.1999.00695.x
  31. Abe J, Kotzin BL, Jujo K, et al. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci U S A 1992;89(9):4066–4070. DOI: 10.1073/pnas.89.9.4066
  32. Reichardt P, Lehmann I, Sierig G, et al. Analysis of T-cell receptor V-beta 2 in peripheral blood lymphocytes as a diagnostic marker for Kawasaki disease. Infection 2002;30(6):360–364. DOI: 10.1007/s15010-002-3063-4
  33. Sakaguchi M, Kato H, Nishiyori A, et al. Characterization of CD4+ T helper cells in patients with Kawasaki disease (KD): preferential production of tumour necrosis factor-alpha (TNF-alpha) by V beta 2- or V beta 8-CD4+ T helper cells. Clin Exp Immunol 1995;99(2):276–282. DOI: 10.1111/j.1365-2249.1995.tb05545.x
  34. Yamashiro Y, Nagata S, Oguchi S, et al. Selective increase of V beta 2+ T cells in the small intestinal mucosa in Kawasaki disease. Pediatr Res 1996;39(2):264–266. DOI: 10.1203/00006450-199602000-00013
  35. Leung DY, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993;342((8884):1385–1388. DOI: 10.1016/0140-6736(93)92752-F
  36. Leung DY, Meissner HC, Shulman ST, et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J Pediatr 2002;140(6):742–746. DOI: 10.1067/mpd.2002.123664
  37. Sato K, Ouchi K, Taki M. Yersinia pseudotuberculosis infection in children, resembling Izumi fever and Kawasaki syndrome. Pediatr Infect Dis 1983;2(2):123–126. DOI: 10.1097/00006454-198303000-00011
  38. Chiba S, Kaneko K, Hashimoto N, et al. Yersinia pseudotuberculosis and Kawasaki disease. Pediatr Infect Dis 1983;2(6):494. DOI: 10.1097/00006454-198311000-00025
  39. Vincent P, Salo E, Skurnik M, et al. Similarities of Kawasaki disease and Yersinia pseudotuberculosis infection epidemiology. Pediatric Infect Dis J 2007;26(7):629–631. DOI: 10.1097/INF.0b013e3180616d3c
  40. Salo E, Pelkonen P, Pettay O. Outbreak of Kawasaki syndrome in Finland. Acta Paediatr Scand 1986;75(1):75–80. DOI: 10.1111/j.1651-2227.1986.tb10160.x
  41. Tertti R, Granfors K, Lehtonen OP, et al. An outbreak of Yersinia pseudotuberculosis infection. J Infect Dis 1984;149(2):245–250. DOI: 10.1093/infdis/149.2.245
  42. Tahara M, Baba K, Waki K, et al. Analysis of Kawasaki disease showing elevated antibody titres of Yersinia pseudotuberculosis. Acta Paediatr 2006;95(12):1661–1664. DOI: 10.1080/08035250600750080
  43. Horinouchi T, Nozu K, Hamahira K, et al. Yersinia pseudotuberculosis infection in Kawasaki disease and its clinical characteristics. BMC Pediatr 2015;15:177. DOI: 10.1186/s12887-015-0497-2
  44. Fukushima H, Matsuda Y, Seki R, et al. Geographical heterogeneity between far eastern and western countries in prevalence of the virulence plasmid, the superantigen Yersinia pseudotuberculosis-derived mitogen, and the high-pathogenicity island among Yersinia pseudotuberculosis strains. J Clin Microbiol 2001;39(10):3541–3547. DOI: 10.1128/JCM.39.10.3541-3547.2001
  45. Hassan SM, Doolittle BR. A case of Yersinia enterocolitica mimicking Kawasaki disease. Rheumatology (Oxford) 2009;48(7):857–858. DOI: 10.1093/rheumatology/kep076
  46. Haidar-Alame S, Raudszus A, Sahai S, et al. A child with Kawasaki disease and Yersinia enterocolitica infection: a closer look at pathogenesis. Glob Pediatr Health 2015;2:2333794X15591563. DOI: 10.1177/2333794X15591563
  47. Abe J, Takeda T, Watanabe Y, et al. Evidence for superantigen production by Yersinia pseudotuberculosis. J Immunol 1993;151(8):4183–4188.
  48. Uchiyama T, Miyoshi-Akiyama T, Kato H, et al. Superantigenic properties of a novel mitogenic substance produced by Yersinia pseudotuberculosis isolated from patients manifesting acute and systemic symptoms. J Immunol 1993;151(8):4407–4413.
  49. Miyoshi-Akiyama T, Fujimaki W, Yan XJ, et al. Identification of murine T cells reactive with the bacterial superantigen Yersinia pseudotuberculosis-derived mitogen (YPM) and factors involved in YPM-induced toxicity in mice. Microbiol Immunol 1997;41(4):345–352. DOI: 10.1111/j.1348-0421.1997.tb01211.x
  50. Goubard A, Loïez CInfect Immun, Abe J, et al. Superantigenic Yersinia pseudotuberculosis induces the expression of granzymes and perforin by CD4+ T cells. 2015;83(5):2053–2064. DOI: 10.1128/IAI.02339-14
  51. Wang JN, Wang SM, Liu CC, et al. Mycoplasma pneumoniae infection associated with Kawasaki disease. Acta Paediatr 2001;90(5):594–595. DOI: 10.1111/j.1651-2227.2001.tb00810.x
  52. Ebrahim M, Gabay M, Rivas-Chacon RF. Evidence of acute mycoplasma infection in a patient with incomplete and atypical Kawasaki disease: a ortcase repCase Rep Med. 2011;2011:606920. DOI: 10.1155/2011/606920
  53. Lee MN, Cha JH, Ahn HM, et al. Mycoplasma pneumoniae infection in patients with Kawasaki disease. Korean J Pediatr 2011;54(3):123–127. DOI: 10.3345/kjp.2011.54.3.123
  54. Tang Y, Yan W, Sun L, et al. Kawasaki disease associated with Mycoplasma pneumoniae. Ital J Pediatr 2016;42(1):83. DOI: 10.1186/s13052-016-0292-1
  55. Park HR, Han MY, Yoon KL, et al. Mycoplasma infection as a cause of persistent fever after intravenous immunoglobulin treatment of patients with Kawasaki disease: frequency and clinical impact. Infect Chemother 2017;49(1):38–43. DOI: 10.3947/ic.2017.49.1.38
  56. Nanishi E, Nishio H, Takada H, et al. Clarithromycin plus intravenous immunoglobulin therapy can reduce the relapse rate of Kawasaki disease: a phase 2, open-label, randomized control study. J Am Heart Assoc 2017;6(7):e005370. DOI: 10.1161/JAHA.116.005370
  57. Meilleur CE, Wardell CM, Mele TS, et al. Bacterial superantigens expand and activate, rather than delete or incapacitate, preexisting antigen-specific memory CD8+ T cells. J Infect Dis 2019;219(8): 1307–1317. DOI: 10.1093/infdis/jiy647
  58. Kakisaka Y, Ohara T, Katayama S, et al. Human herpes virus type VI can cause skin lesions at the BCG inoculation site similar to Kawasaki disease. Tohoku J Exp. Med 2012;228(4):351–353. DOI: 10.1620/tjem.228.351
  59. Muthuvelu S, Lim KS, Huang LY, et al. Measles infection causing bacillus Calmette-Guérin reactivation: a case repBMC Pediatrort. 2019;19(1):251. DOI: 10.1186/s12887-019-1635-z
  60. Sireci G, Dieli F, Salerno A. T cells recognize an immunodominant epitope of heat shock protein 65 in Kawasaki disease. Mol Med 2000;6(7):581–590. DOI: 10.1007/BF03401796
  61. Yokota S, Tsubaki K, Kuriyama T, et al. Presence in Kawasaki disease of antibodies to mycobacterial heat-shock protein hsp65 and autoantibodies to epitopes of human hsp65 cognate antigen. Clin Immunol Immunopathol 1993;67(2):163–170. DOI: 10.1006/clin.1993.1060
  62. Yamashiro Y, Nagata S, Ohtsuka Y, et al. Microbiologic studies on the small intestine in Kawasaki disease. Pediatr Res 1996;39(4 Pt 1): 622–624. DOI: 10.1203/00006450-199604000-00010
  63. Nagata S, Yamashiro Y, Ohtsuka Y, et al. Heat shock proteins and superantigenic properties of bacteria from the gastrointestinal tract of patients with Kawasaki disease. Immunology 2009;128(4):511–520. DOI: 10.1111/j.1365-2567.2009.03135.x
  64. Nagata S, Yamashiro Y, Maeda M, et al. Immunohistochemical studies on small intestinal mucosa in kawasaki disease. Pediatr Res 1993;33(6):557–563. DOI: 10.1203/00006450-199306000-00004
  65. Takeshita S, Kobayashi I, Kawamura Y, et al. Characteristic role of intestinal microflora in Kawasaki disease. Acta Pediatr 2001;91(7): 783–788. DOI: 10.1111/j.1651-2227.2002.tb03327.x
  66. Oh NS, Joung JY, Lee JY, et al. Probiotic and anti-inflammatory potential of lactobacillus rhamnosus 4B15 and lactobacillus gasseri 4M13 isolated from infant feces. PLoS One 2018;13(2):e0192021. DOI: 10.1371/journal.pone.0192021
  67. Uchinaka A, Azuma N, Mizumoto H, et al. Anti-inflammatory effects of heat-killed Lactobacillus plantarum L-137 on cardiac and adipose tissue in rats with metabolic syndrome. Sci Rep 2018;8(1):8156. DOI: 10.1038/s41598-018-26588-x
  68. Kim DH, Kim S, Lee JH, et al. Lactobacillus acidophilus suppresses intestinal inflammation by inhibiting endoplasmic reticulum stress. J Gastroenterol Hepatol 2019;34(1):178–185. DOI: 10.1111/jgh.14362
  69. Lee SH, Kwon JY, Jhun J, et al. Lactobacillus acidophilus ameliorates pain and cartilage degradation in experimental osteoarthritis. Immunol Lett 2018;203:6–14. DOI: 10.1016/j.imlet.2018.07.003
  70. Pagnini C, Corleto VD, Martorelli M, et al. Mucosal adhesion and anti-inflammatory effects of lactobacillus rhamnosus GG in the human colonic mucosa: a proof-of-concept study. World J Gastroenterol 2018;24(41):4652–4662. DOI: 10.3748/wjg.v24.i41.4652
  71. Liu J, Gu Z, Song F, et al. Lactobacillus plantarum ZS2058 and Lactobacillus rhamnosus GG use different mechanisms to prevent salmonella infection in vivo. Front Microbiol 2019;10:299. DOI: 10.3389/fmicb.2019.00299
  72. Noh SY, Kang SS, Yun CH, et al. Lipoteichoic acid from Lactobacillus plantarum inhibits Pam2CSK4-induced IL-8 production in human intestinal epithelial cells. Mol Immunol 2015;64(1):183–189. DOI: 10.1016/j.molimm.2014.11.014
  73. Kinumaki A, Sekizuka T, Hamada H, et al. Characterization of the gut microbiota of Kawasaki disease patients by metagenomic analysis. Front Microbiol 2015;6:824. DOI: 10.3389/fmicb.2015.00824
  74. Rodó X, Ballester J, Cayan D, et al. Association of Kawasaki disease with tropospheric wind patterns. Sci Rep 2011;1:152. DOI: 10.1038/srep00152
  75. Rodó X, Curcoll R, Robinson M, et al. Tropospheric winds from Northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan. Proc Natl Acad Sci U S A 2014;111(22): 7952–7957. DOI: 10.1073/pnas.1400380111
  76. El-Askary H, LaHaye N, Linstead E, et al. Remote sensing observation of annual dust cycles and possible causality of Kawasaki disease outbreaks in Japan. Glob Cardiol Sci Pract 2017;2017(3):e201722. DOI: 10.21542/gcsp.2017.22
  77. Jorquera H, Borzutzky A, Hoyos-Bachiloglu R, et al. Association of Kawasaki disease with tropospheric winds in central chile: is wind-borne desert dust a risk factor? Environ Int 2015;78:32–38. DOI: 10.1016/j.envint.2015.02.007.
  78. Frazer J. Infectious disease: blowing in the wind. Nature 2012;484(7392):21–23. DOI: 10.1038/484021a
  79. Shinn EA, Smith GW, Prospero JM, et al. African dust and the demise of Caribbean coral reefs. Geophys Res Lett 2000;27(19):3029–3032. DOI: 10.1029/2000GL011599
  80. Banday AZ, Neelam H, Singh MP, et al. Severe lip excoriation in Kawasaki disease: beware of herpes simplex virus. Rheumatology (Oxford) 2020. keaa081. DOI:10.1093/rheumatology/keaa081
  81. Kumrah R, Vignesh P, Rawat A, et al. Immunogenetics of Kawasaki disease. Clin Rev Allergy Immunol 2020. DOI: 10.1007/s12016-020-08783-9
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.